{
    "clinical_study": {
        "@rank": "163145", 
        "acronym": "HEMO-TIN", 
        "arm_group": [
            {
                "arm_group_label": "Tinzaparin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Unfractionated Heparin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness\n      (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in\n      hemodialysis patients."
        }, 
        "brief_title": "Use of Tinzaparin for Anticoagulation in Hemodialysis", 
        "condition": "Kidney Failure, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >= 18 years\n\n          -  End stage renal disease maintained on outpatient hemodialysis for >= 3 months\n\n          -  Frequency of hemodialysis: 3 times per week\n\n          -  Anticoagulation with an unfractionated heparin protocol for at least 4 weeks\n\n          -  Patient or legal guardian able to provide written consent\n\n          -  Baseline INR <= 1.3\n\n          -  Baseline platelet count >= 80,000 x 10^9/L\n\n        Exclusion Criteria:\n\n          -  Therapeutic systemic anticoagulation\n\n          -  Clinically apparent bleeding in the last 2 months\n\n          -  High risk of bleeding\n\n          -  Planned major surgery in the next 4 months\n\n          -  Major surgery in the past 48 hours\n\n          -  Pregnant or lactating\n\n          -  Child bearing potential\n\n          -  Allergy/intolerance to heparin or history of heparin induced thrombocytopenia\n\n          -  Current participation in a related randomized drug trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930396", 
            "org_study_id": "13-7822377"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tinzaparin", 
                "intervention_name": "Tinzaparin", 
                "intervention_type": "Drug", 
                "other_name": "Innohep"
            }, 
            {
                "arm_group_label": "Unfractionated Heparin", 
                "intervention_name": "Unfractionated Heparin", 
                "intervention_type": "Drug", 
                "other_name": "Heparin LEO"
            }, 
            {
                "arm_group_label": "Unfractionated Heparin", 
                "description": "0.9% Normal Saline", 
                "intervention_name": "Placebo (for Tinzaparin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tinzaparin", 
                "description": "0.9% Normal Saline", 
                "intervention_name": "Placebo (for Unfractionated Heparin)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin", 
                "Tinzaparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hemodialysis", 
            "Anticoagulation", 
            "Tinzaparin", 
            "Unfractionated Heparin", 
            "Randomized Controlled Trial"
        ], 
        "lastchanged_date": "August 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamilton", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L8N 4A6"
                }, 
                "name": "St. Joseph's Healthcare Hamilton"
            }, 
            "investigator": [
                {
                    "last_name": "Dr. Christine M Ribic, MD, MSc", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Dr. Mark A Crowther, MD, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dr. Azim S Gangji, MD, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dr. Deborah J Cook, MD, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dr. Michael Walsh, MD, PhD, MSc", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)", 
        "overall_contact": {
            "email": "christine.ribic@medportal.ca", 
            "last_name": "Dr. Christine M Ribic, MD, MSc", 
            "phone": "905-522-1155", 
            "phone_ext": "33261"
        }, 
        "overall_contact_backup": {
            "email": "twilkies@stjoes.ca", 
            "last_name": "Trevor J Wilkieson, MSc", 
            "phone": "905-522-1155", 
            "phone_ext": "35164"
        }, 
        "overall_official": {
            "affiliation": "St. Joseph's Healthcare Hamilton/McMaster University", 
            "last_name": "Dr. Christine M Ribic, MD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of major, clinically important non-major or minor bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930396"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Joseph's Healthcare Hamilton", 
            "investigator_full_name": "Christine Ribic", 
            "investigator_title": "Nephrologist", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Clotting in extracorporeal dialysis circuit", 
            "safety_issue": "Yes", 
            "time_frame": "During Hemodialysis (weekly for 26 weeks)"
        }, 
        "source": "St. Joseph's Healthcare Hamilton", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "McMaster University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "LEO Pharma", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Christine Ribic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}